Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Pediatric Study Bill Clears Senate, Will Sunset With Exclusivity Grants

Executive Summary

Legislation restoring FDA's authority to require drug sponsors to conduct trials in children would sunset at the same time as the pediatric exclusivity incentive program under a bill adopted by the Senate July 23
Advertisement

Related Content

Pediatric Study Requests Would Benefit From Input On Trial Design – Cmte.
Pediatric Study Requests Would Benefit From Input On Trial Design – Cmte.
Pediatric Wish List: Longer Exclusivity Reviews, More Public Data
Pediatric Wish List: Longer Exclusivity Reviews, More Public Data
Pediatric Study Planning Should Occur Early In Drug Development, FDA Says
SSRIs And Suicide To Be Discussed By Pediatric Advisory Cmte. In September
House passes pediatric bill
Pediatric Formulations Of Oral Oncologics Sought By FDA
Pediatric Exclusivity: 36% Of Studies Lead To Significant New Labeling – FDA
Pediatric rule bill goes to Senate
Advertisement
UsernamePublicRestriction

Register

PS042194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel